Zymic Technology (ZYMIQ) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 reached SEK 812 thousand, nearly doubling from SEK 416 thousand in Q1 2024, reflecting growing market traction for enzyme-based products.

• Loss after tax narrowed to SEK -2,063 thousand from SEK -2,179 thousand year-over-year, with EPS improving to SEK -0.24 from SEK -0.30.

• Cash and cash equivalents increased to SEK 2,257 thousand from SEK 724 thousand a year earlier, supported by a SEK 23.8 million capital raise during the quarter.

• The company is preparing for an IPO in Q4 2025 and is planning a directed share issue as the next step in its growth strategy.

Financial highlights

• Gross margin for Q1 2025 was 30%, down from 82% in Q1 2024, but up from 16% in Q4 2024.

• Operating loss for Q1 2025 was SEK -2,104 thousand, compared to SEK -2,205 thousand in Q1 2024.

• Cash flow for the quarter was negative SEK -932 thousand, compared to SEK -427 thousand in Q1 2024.

• Equity at quarter-end was SEK 17,925 thousand, up from SEK 8,967 thousand a year earlier.

Outlook and guidance

• The company anticipates continued sales growth as new products gain traction and additional markets are entered.

• An IPO is targeted for Q4 2025, with ongoing preparations and a focus on organizational scalability.